Press Room

Article / Mar 01, 2005

Hovione: More Than Just Very Good

Drug Delivery Technology, March 2005

Interview with Hovione's CEO, Guy Villax.

“Many of the new compounds in development present significant challenges. For example, they may be very fragile, and in simple terms, galenic techniques enable the chemist to isolate the API already in a preformulated more stable form. We call these Enhanced APIs.”

There is much talk about the convergence of disciplines in the life-sciences area. Hovione has been involved in manufacturing APIs under current cGMP for nearly 50 years. Many development candidates present an increasing set of challenges: complexity of the molecule, poor bioavailability yet highly potent, very high purity, poor stability, etc.....often simultaneously. Meeting these demands has opened opportunities for the “top-of-the-line” Contract Manufacturing Organizations to develop strengths in new disciplines and to combine capabilities never before found on the same campus, let alone within a validated commercial scale GMP environment. Hovione has traditionally been a CMO of small molecules and is now adding new skills and capabilities that address the special needs of large molecules, peptides, and antibodies. Hence, Hovione now offers a range of galenic enhancements that contribute decisively to making certain APIs into viable industrial propositions, in purpose-designed containment areas built to uncommon standards, to serve projects managed with multidisciplinary staff. Drug Delivery Technology recently interviewed Mr. Guy Villax, Hovione’s CEO, to discuss his company’s philosophy and business strategy, a vision based on an intimate understanding of client needs and technology trends. APIs of the 21st century present increased difficulties not only in their traditional fields (chemistry, engineering, analytical chemistry), but in new areas of technology as well as management.

 

 

Small-molecule chemistry

 

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024